576.98
Schlusskurs vom Vortag:
$567.89
Offen:
$567.89
24-Stunden-Volumen:
769.29K
Relative Volume:
0.79
Marktkapitalisierung:
$60.10B
Einnahmen:
$14.21B
Nettoeinkommen (Verlust:
$4.46B
KGV:
14.54
EPS:
39.68
Netto-Cashflow:
$3.56B
1W Leistung:
-1.46%
1M Leistung:
-2.12%
6M Leistung:
-12.71%
1J Leistung:
-44.84%
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Vergleichen Sie REGN mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
2025-06-30 | Herabstufung | Argus | Buy → Hold |
2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2025-01-16 | Herabstufung | UBS | Buy → Neutral |
2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
2024-11-14 | Eingeleitet | Citigroup | Neutral |
2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
2024-03-12 | Eingeleitet | Bernstein | Outperform |
2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
2023-08-21 | Bestätigt | Oppenheimer | Perform |
2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
2022-06-06 | Eingeleitet | Jefferies | Underperform |
2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
2021-12-07 | Fortgesetzt | Cowen | Market Perform |
2021-12-06 | Eingeleitet | Goldman | Buy |
2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
2020-02-27 | Eingeleitet | Barclays | Overweight |
2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
2020-02-11 | Hochstufung | Argus | Hold → Buy |
2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
2019-11-12 | Eingeleitet | SunTrust | Hold |
2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target - MSN
Regeneron at Bernstein Forum: Strategic Growth & Challenges By Investing.com - Investing.com Canada
Diversified Trust Co Acquires 1,015 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Golden State Equity Partners Has $459,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron’s Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide - Yahoo Finance
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Sells 10,460 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Procyon Advisors LLC Sells 5,942 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Biotech Stocks Facing FDA Decision In October 2025 - RTTNews
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MSN
Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises - Seeking Alpha
Avanza Fonder AB Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron (REGN) Stock Is Down Today - Yahoo Finance
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap DownHere's Why - MarketBeat
Should European Dupixent Approval Recommendation Prompt Regeneron (REGN) Investors to Reevaluate Growth Potential? - simplywall.st
US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall - Reuters
Eaton Financial Holdings Company LLC Takes $494,000 Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Assenagon Asset Management S.A. Sells 58,064 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $817.67 Consensus Target Price from Analysts - MarketBeat
Kingstone Capital Partners Texas LLC Invests $40.74 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Sees Significant Growth in Short Interest - MarketBeat
Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight - GlobeNewswire Inc.
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU - Yahoo Finance
All Eyes on ELYEA–Sandoz Defeats Preliminary Injunction - The National Law Review
Founders Capital Management LLC Purchases 538 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Clear Harbor Asset Management LLC - MarketBeat
Sanofi (SNY) Advances with Dupixent for Skin Condition in EU - GuruFocus
Alvotech Files PGR Against Regeneron High-Dose Aflibercept Patent - MarketScreener
Exchange Traded Concepts LLC Buys 588 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sovran Advisors LLC Invests $2.75 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi, Regeneron's Chronic Spontaneous Urticaria Drug Lands Positive Recommendation in Europe - MarketScreener
Czech National Bank Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron and Sanofi Announce Positive CHMP Opinion for Dupixent® in Treating Chronic Spontaneous Urticaria in the European Union - Quiver Quantitative
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion - The Manila Times
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion - The Manila Times
Regeneron Pharmaceuticals Inc says Dupixent (dupilumab) to treat chronic spontaneous urticaria (csu) advances in EU with positive CHMP opinion - MarketScreener
Bond Watch: Why is Regeneron Pharmaceuticals Inc stock going downPortfolio Performance Report & Technical Pattern Based Buy Signals - خودرو بانک
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - MSN
How the Narrative for Regeneron Has Shifted with Pipeline Wins and Analyst Optimism - Yahoo Finance
Woodstock Corp Purchases 906 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What are the future prospects of Regeneron Pharmaceuticals IncGlobal Markets & Entry Point Strategy Guides - خودرو بانک
Signal Recap: What are the future prospects of Regeneron Pharmaceuticals IncJuly 2025 Sector Moves & Safe Capital Growth Tips - خودرو بانک
Regeneron To Pit Lynozyfic Against J&J’s Darzalex In Smoldering Myeloma - insights.citeline.com
Regeneron Pharmaceuticals, Inc. $REGN Holdings Decreased by Harbor Investment Advisory LLC - MarketBeat
Applying chart zones and confluence areas to Regeneron Pharmaceuticals Inc.Portfolio Return Report & High Accuracy Swing Entry Alerts - newser.com
Market Pulse: Whats the RSI of General Motors Company stock2025 Support & Resistance & Safe Capital Investment Plans - khodrobank.com
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study - Reuters
Regeneron’s Lynozyfic yields 100% response rate in small smoldering multiple myeloma study - Endpoints News
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):